ArticlePloS one2018
Body mass index and weight change during initial period of chemotherapy affect survival outcome in advanced biliary tract cancer patients.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies.ESMO open · 2024Pooled it
- A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer.Cancer research and treatment · 2024Trial
- Association of subcutaneous adiposity with survival outcomes in advanced biliary tract cancer treated with gemcitabine, cisplatin, and immune checkpoint inhibitor.Journal of gastroenterology · 2026Article
- Incidence and Factors Influencing Locomotive Syndrome in Cancer Patients Living in the Community.Cureus · 2025Article
- A retrospective analysis of the association of obesity with anthracycline- and trastuzumab-induced cardiotoxicity in the treatment of breast cancer and lymphoma.Archives of medical science : AMS · 2025Article
- Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation.Journal of gastroenterology · 2024Article
- Development of a nomogram to predict survival in advanced biliary tract cancer.Scientific reports · 2023Article
- Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer.JHEP reports : innovation in hepatology · 2022Article
- Caution, "normal" BMI: health risks associated with potentially masked individual underweight-EPMA Position Paper 2021.The EPMA journal · 2021Article
- Article
- Dual energy computed tomography analysis in cancer patients: What factors affect iodine concentration in contrast enhanced studies?European journal of radiology · 2019Article
- The impact of skeletal muscle mass on survival outcome in biliary tract cancer patients.PloS one · 2018Article
- C-reactive Protein-to-Albumin Ratio as a Superior Inflammatory Marker in Resected Biliary Tract Cancer: Development of a Prognostic Nomogram Complementary to TNM Staging.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of obesity on survival is known to vary in different cancers. Advanced biliary tract cancer was rarely analyzed about the relationship between obesity and prognosis. We performed this study to evaluate the BMI and body weight change as prognostic factors for advanced biliary tract cancer patients with palliative chemotherapy.
methodsBetween January 2005 and December 2016, two hundred and seventy-six patients who underwent chemotherapy for biliary tract cancer were retrospectively analyzed. The relationship between BMI (kg/m2) and clinical outcomes including overall and progression-free survival was assessed. Additionally the relationship between change in body composition and overall survival was evaluated.
resultsMedian overall survival was 9.7 months for underweight patients, 10.1 months for normal patients, 15.8 months for overweight group, 13.1 months for obese patients, respectively. (p = 0.047) Univariate analysis showed that BMI, stage III, age less than 64 year-old, gallbladder cancer, operation, radiotherapy and ECOG performance were significantly associated with better survival. Compared with normal patients, overweight patients (BMI 23-24.9kg/m2) had a reduced risk of mortality in multivariate analysis (HR 0.632; 95% CI 0.436-0.918, p = 0.016). In the additional analysis for the effect of changes in body weight and BMI to the overall survival, decrease in body weight and BMI (HR 1.410, 95% CI 1.168-1.986, p = 0.046) was associated with a shorter in overall survival.
conclusionOverweight status and the maintenance of body weight during the initial period of chemotherapy are important and independent predictors of better overall survival in advanced biliary tract cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.